Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 147 от 240

Not yet recruiting Phase 1/2

Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy

Nonsquamous Nonsmall Cell Neoplasm of Lung

Maitake is reported with immunomodulatory functions against tumor growth in terms of its unique molecular structure, β-glucan polysaccharides within 1, 6 main chain having 1, 3 branches and a 1, 3 main chain having 1, 6 branches configuration. The β-glucan is identified as a main component of BLEX 404. Not only with therapeutic potential on several types of cancer, BLEX 404 has also shown the potential to improve hematopoiesis, granulocyte colony stimulating factor (G-CSF) production, and the cytotoxicity activity of immune cells in recent animal studies. Its antitumor effect on tumor-bearing mice is exerted by enhancing the immune system through activation of macrophages, T cells, and natural killer (NK) cells. The activation of antigen presenting cells (APCs) such as macrophages, dendritic cells (DCs) via BLEX 404 administration is in response to secretion of interleukin-12 (IL-12). BLEX 404 has been found to enhance the activity of immunocompetent cells such as helper T cells, cytotoxic T cells, and NK cells either by i.p injection or oral intake, therefore, it stimulates innate and adaptive immunity. BLEX 404 enhances hematopoiesis by increasing mouse bone marrow cell and human cord blood cell differentiation into granulocytes-macrophages (GMs), granulopoiesis and mobilization of granulocytes, and granulocyte macrophage colony-stimulating factor (GM-CSF) or G-CSF production. One related phase I healthy human trial by treating with Maitake D-fraction was examined in Italy. The published data of trial for solid tumor patients was in the year 2003 in Japan, and another for breast cancer patients was in the year 2009 in the United States executed by Memorial Sloan Kettering Cancer Center (MSKCC). Lately, same team amended IND for myelodysplastic syndromes (MDS) human trial. All those human experiences are the fundamental of developing BLEX 404 Oral Liquid.

Начало: 01.12.2026 Край: 31.12.2028 Възраст: 20–70 г.

Taiwan Rgene Corporation NCT05764928

Not yet recruiting Phase 2

NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI

Spinal Cord Injuries Autonomic Dysreflexia

This project aims to evaluate the safety and efficacy of using a short-acting drug to reduce the maximal blood pressure during dangerous blood pressure spikes that happen during bowel care in individuals with spinal cord injury. the investigators will monitor the physiological effects of this drug during at-home bowel care to best understand the drug's effects in typical use.

Начало: 01.12.2026 Край: 01.02.2028 Възраст: 19–80 г.

Simon Fraser University NCT05635851

Not yet recruiting Phase 2

A Randomised Controlled Trial to Establish Whether Dapagliflozin and Spironolactone in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement, Result in Better Left Ventricular Mass Regression, Myocardial Health and Patient Reported Outcomes Than Standard-of-care Therapy Alone.

Aortic Stenosis

This trial aims to improve the heart health of people with a narrowed aortic valve called aortic stenosis (AS) who have their valve replaced through aortic valve replacement (AVR) by assessing the change in the mass of the left ventricle. In many patients even after an AVR, the heart still is unable to pump as well and can lead to heart failure. This study will assess if medication used in other causes of heart failure can help patients having an AVR recover better. It will assess two drugs, dapagliflozin and spironolactone, that have been shown to help patients with heart failure who do not have AS. We hope that taking one or both medicines together will help patients with AS. There will be four treatment arms: dapagliflozin, spironolactone, dapagliflozin and spironolactone together, and standard of care. These will be taken as one tablet of each IMP per day for 12 months. Participants will have approximately four follow up visits, dependent on the treatment arm - those in an arm with spironolactone will have an extra safety follow up visit. These medicines might help patients after AVR by reducing heart muscle thickness and scarring.

Начало: 01.12.2026 Край: 28.02.2030 Възраст: от 18 г.

University College, London NCT07539259

Not yet recruiting Phase 2

Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer

Malignant Neoplasm

The goal of this research study is to understand the effect of inhalation approaches in reducing nausea in cancer patients.

Начало: 05.11.2026 Край: 30.12.2028 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT04181463

Not yet recruiting Phase 2

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

Lung Transplant

This study is testing a medication called emapalumab to see if it can help people who have had a lung transplant and are experiencing a sudden drop in lung function, called acute lung allograft dysfunction (ALAD). ALAD is a serious condition that can happen after a lung transplant and can lead to worsening breathing and other complications. Right now, there is no approved treatment for ALAD. The main goal is to see if lung function improves, meaning it returns close to your usual (baseline) level within 90 days.

Начало: 02.11.2026 Край: 01.11.2028 Възраст: от 18 г.

United States University of California, San Francisco NCT07538336

Not yet recruiting Phase 4

Metabolic Surgery for Atrial Fibrillation Elimination

Atrial Fibrillation Obesity and Obesity-related Medical Conditions

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation. The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.

Начало: 01.11.2026 Край: 31.03.2030 Възраст: 18–80 г.

United States Ali Aminian NCT07027969

Not yet recruiting

Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass

Fibrinogen Deficiency in Complex Cardiac Surgery

Heart surgery is essential for many cardiovascular conditions, but it is a major operation with a significant mortality rate of around 4% in Europe. Among the main complications encountered postoperatively, hemorrhage occurs at a rate of around 8.2% for severe bleeding and 1.6% for massive bleeding. Hemorrhagic complications are caused by hemostasis disorders attributable to extracorporeal circulation (ECC). Despite recent advances in material design, ECG activates hemostasis, leading to the consumption of various coagulation factors, including fibrinogen, as well as the absorption of fibrinogen by the various components of the circuit. Postoperative hypofibrinogenemia has multiple causes and is correlated with the risk of bleeding and the need for red blood cell transfusions in cardiac surgery under CPB, and therefore indirectly with mortality related to this procedure. The administration of fibrinogen concentrates is the standard treatment; however, the optimal dose to normalize fibrinogen levels and reduce bleeding is unknown. Good practice recommendations in cardiac surgery suggest administering fibrinogen in cases of bleeding associated with fibrinogen levels below 2 g/L. However, the time required to obtain fibrinogen level results from the laboratory (approximately 1 hour) is not always compatible with the urgency of transfusion needs in these situations. Transfusion optimization strategies have been proposed using viscoelastic tests (ROTEM, Werfen, or Quantra, Stago, for example). The administration of fibrinogen guided by these tests has reduced the need for red blood cell transfusions; however, this strategy increases the cost attributable to fibrinogen because it favors its administration without individualizing the dose to be administered. To date, it is not possible to individualize the dose of fibrinogen to be administered based on baseline fibrinogen levels and kinetics. Developing such an administration strategy would allow for i) faster correction of hypofibrinogenemia and ii) a reduction in associated costs by administering the minimum effective dose.

Начало: 01.11.2026 Край: 07.11.2028 Възраст: от 18 г.

France Centre Hospitalier Universitaire de Saint Etienne NCT07425600

Not yet recruiting

Role of Medical Thoracoscopy in Pleural Infection (PROMPT Trial)

Pleural Infection Pleural Infections Pleural Infections and Inflammations

The PROMPT study is testing whether an early keyhole procedure called Medical Thoracoscopy, which lets doctors look inside the chest and remove infected fluid, works better than current standard treatment (medicines to break up thick fluid) for people with pleural infection. About 170 patients in several hospitals will be randomly assigned to one of the two treatments, and researchers will see which approach results in fewer additional procedures-such as another drain or surgery-within 30 days, as well as how quickly people recover and whether they experience any complications. Everyone in the study receives high-quality care, and the results will help doctors better understand which treatment gives patients the best chance of recovering quickly and safely

Начало: 01.11.2026 Край: 31.03.2029 Възраст: от 18 г.

Università Politecnica delle Marche NCT07550530

Not yet recruiting Phase 2

Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

Phase II Imetelstat Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases

To learn if imetelstat can help to control MDS/MPNs.

Начало: 08.10.2026 Край: 31.05.2027 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT07549451

Not yet recruiting

The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study

Venous Thromboses Venous Disease Venous Leg Ulcer Venous Stasis +4

This study is a prospective, multicenter, single-arm post-market clinical study to evaluate the GORE® VIABAHN® FORTEGRA Venous Stent in real-world use.

Начало: 07.10.2026 Край: 01.05.2031 Възраст: от 18 г.

W.L.Gore & Associates NCT07538609

Not yet recruiting

taVNS Treatment for Fibromyalgia

Fibromyalgia

In this research study we want to learn more about if transcutaneous electrical nerve stimulation (TENS), a safe electrical stimulation tool, can relieve Fibromyalgia pain. A total of 60 subjects with Fibromyalgia will be enrolled in this study at Massachusetts General Hospital, Charlestown Navy Yard campus.

Начало: 03.10.2026 Край: 01.03.2027 Възраст: 18–65 г.

United States Massachusetts General Hospital NCT04777500

Not yet recruiting

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

Metastatic Bladder Cancer Peripheral Neuropathy Advanced Urothelial Cancer Metastatic Urothelial Cancer

The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro). The names of the two study groups in this research study are: * Acupuncture + Virtual Exercise (AVE) * Virtual Exercise Only (VE)

Начало: 02.10.2026 Край: 02.03.2027 Възраст: от 18 г.

United States Dana-Farber Cancer Institute NCT07548476

Not yet recruiting Phase 1

Study of STLX-2012 in Healthy Volunteers

Healthy Participants

The purpose of this research is to establish the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single IV dose of STLX-2012.

Начало: 01.10.2026 Край: 01.02.2027 Възраст: 18–55 г. Basic science

Australia Stelexis BioSciences NCT07231744

Not yet recruiting Phase 1/2

Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

Persistent HPV16 Infection

This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.

Начало: 01.10.2026 Край: 01.11.2027 Възраст: 18–60 г.

United States Newish Biotech (Wuxi) Co., Ltd. NCT07536282

Not yet recruiting

ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

Rectal Cancer Non Metastatic Rectal Cancer

This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy. This research study involves the collection of data and biospecimens (blood and tissue) to see if the presence of circulating tumor DNA (genetic material) ctDNA will help monitor rectal cancer more closely and potentially detect a recurrence before routine scans, performed per standard of care C2i Genomics, a biotechnology company, and the Spier Foundation are supporting this research study by providing funding for the study.

Начало: 01.10.2026 Край: 01.06.2030 Възраст: от 18 г.

United States Massachusetts General Hospital NCT05629442

Not yet recruiting

AI-Assisted Workflow for Occult Atrial Fibrillation Detection After Ischemic Stroke: A Prospective Randomized Trial

Atrial Fibrillation Stroke Artificial Intelligence

We hypothesize that an AI-guided AF risk stratification approach, particularly when combined with intensified rhythm monitoring using wearable devices and extended ECG patches, will significantly increase AF detection rates compared with standard care. By enabling earlier identification of patients who may benefit from anticoagulation therapy, this strategy has the potential to improve clinical outcomes while minimizing unnecessary exposure to anticoagulant-related bleeding risks. Ultimately, this trial seeks to provide robust clinical evidence supporting the integration of AI-assisted ECG analysis into routine post-stroke care, advancing precision medicine and optimizing resource allocation for patients with ischemic stroke.

Начало: 01.10.2026 Край: 31.12.2028 Възраст: от 18 г.

Taiwan National Taiwan University Hospital NCT07540065

Not yet recruiting

Clinical Comparison of Cariclast Gel and Rotary Drilling Technique for Caries Removal in 2d Primary Molars

Dental Caries in Primary Molars

This randomized clinical trial aims to compare two different methods of caries removal in primary molars: the chemomechanical technique using Cariclast gel and the conventional rotary drilling method. The study will evaluate and compare the pain perception, patient acceptance, and operative time associated with both techniques in children aged 5-7years.

Начало: 01.10.2026 Край: 01.10.2027 Възраст: 4–7 г.

Cairo University NCT07270458

Not yet recruiting Phase 3

An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness

Ocular Hyperemia

The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.

Начало: 01.10.2026 Край: 01.11.2027 Възраст: от 18 г.

United States Alcon Research NCT07531043

Not yet recruiting

Multicomponent Intervention to Improve Cognitive Abilities in Older Adults With Mild Cognitive Impairment

Mild Cognitive Impairment (MCI)

The research aims to investigate the effectiveness of a new short-term multicomponent intervention to promote the bio-psycho-social-spiritual health of older adults with MCI to improve their cognitive abilities. In this study, the multicomponent intervention consists of healthy lifestyle psychoeducation and cognitive stimulation. This study is a double-blind, clustered, randomized, controlled, four-arm parallel group study. 200 eligible older adults with MCI are openly recruited into activity groups in local elderly centres. The activity groups are randomly allocated to three intervention groups (i.e., multicomponent intervention, cognitive stimulation and lifestyle psychoeducation) and a control group in a 1:1:1:1 ratio. The participants with MCI are blinded on group allocation and kept uninformed which type of intervention they are receiving. An investigator, blinded to group allocation and intervention, assess outcomes using standardized assessment tools before and after the intervention and after 3 months.

Начало: 01.10.2026 Край: 30.06.2028 Възраст: от 60 г.

Hong Kong City University of Hong Kong NCT07549074

Not yet recruiting Phase 1

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed. The safety of PLM-102 will also be studied.

Начало: 01.10.2026 Край: 01.06.2031 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT07549464

1 … 145 146 147 148 149 … 240